Literature DB >> 10953958

A pilot C282Y hemochromatosis screening in Italian newborns by TaqMan technology.

G Restagno1, A M Gomez, L Sbaiz, M De Gobbi, A Roetto, E Bertino, C Fabris, G C Fiorucci, P Fortina, C Camaschella.   

Abstract

Hereditary hemochromatosis (HH) is a disorder of iron metabolism that leads to iron overload in middle age and can be caused by homozygosity for the C282Y mutation in the HFE gene. Preliminary studies have estimated the frequency of this mutation at 0.5-1% in Italy, but this has not been verified on a large sample. We analyzed 1,331 Italian newborns for the C282Y mutation in the HFE gene using dried blood spots (DBS) from the Neonatal Screening Center in Turin, Italy. The mutation was assessed using a semi-automatable 5'-nuclease assay (TaqMan technology). We detected 55 heterozygotes and no homozygotes in our sampling, resulting in an overall frequency of 2.1% +/- 0.6 for the C282Y allele. Differences in allele frequency were observed, and ranged from 2.7% +/- 1.3 in samples from Northern Italy, to 1.7% +/- 0.9 in samples from Central-Southern Italy. The low frequency of the at-risk genotype for iron overload suggests that genetic screening for HFE in Italy would not be cost effective. The present study, in addition to defining C282Y frequency, documents detection of the major HFE mutation on routine DBS samples from neonatal screening programs using a semi-automatable, rapid, reliable, and relatively inexpensive approach.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953958     DOI: 10.1089/10906570050114894

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  2 in total

1.  Real-time PCR genotyping using displacing probes.

Authors:  Jinping Cheng; Yongyou Zhang; Qingge Li
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

2.  Prevalence of H63D, S65C and C282Y hereditary hemochromatosis gene mutations in Slovenian population by an improved high-throughput genotyping assay.

Authors:  Marko Cukjati; Tomaz Vaupotic; Ruth Rupreht; Vladka Curin-Serbec
Journal:  BMC Med Genet       Date:  2007-11-23       Impact factor: 2.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.